Navigation Links
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:11/1/2008

Interim results of HCV SPRINT-1 study presented at AASLD annual meeting

Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment

SAN FRANCISCO, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that a planned interim analysis of a Phase II study showed that boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with peginterferon and ribavirin markedly increased sustained virologic response (SVR) rates with 28 weeks of therapy and nearly doubled SVR with 48 weeks of therapy compared to current standard of care, peginterferon and ribavirin (control group) for 48 weeks. These results from the HCV SPRINT-1 study in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the 59th American Association for the Study of Liver Diseases (AASLD) Annual Meeting.(1)

In a 48-week boceprevir regimen, the SVR rate was 74 percent at 12 weeks after the end of treatment (SVR 12) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID) (P/R lead-in). In a 28-week boceprevir regimen, the SVR rate was 56 percent at 24 weeks after the end of treatment (SVR 24) in patients who received the P/R lead-in. These results compared to a 38 percent SVR rate (SVR 12) for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(2-4)

Importantly, predictability of attaining SVR 12 or 24 based on rapid virologic response (RVR) was greater for boceprevir patients in the lead-in arms compared to the no lead-in arms. In addition, fewer patients in the lead-in arms discontinued t
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... N.J. and DETROIT , April ... five children live in poverty, the infant mortality rate is ... at 15 per 1,000 live births. Nearly 6 of 10 ... not receive adequate prenatal care.  These are sobering statistics that ... serving the people of Metro Detroit, is poised to change ...
(Date:4/17/2015)... April 17, 2015 Today, the Pharmaceutical ... employees from 12 biopharmaceutical companies as "We Work ... policy advocacy and community service. Established ... Awards were created by the biopharmaceutical industry to ... their careers, but have also shown an outstanding ...
(Date:4/17/2015)... 17, 2015 Sigma-Aldrich Corporation ... and High Technology company, today announced the opening ... headquarters and state-of-the-art Cell Culture Technical Center in ... will provide customized support to meet customer needs, ... "Our new Technical Center will significantly enhance ...
Breaking Medicine Technology:Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 2Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 3Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 4PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5
... HUYA Bioscience International, a company at the ... strategic partnership with the School of Pharmaceutical Sciences at ... foothold in Southern China, aiming to accelerate the development ... The agreement provides HUYA with access to ...
... a pharmacy buying group advancing the growing buying power ... three-year prime vendor agreement with H. D. Smith, a ... with the programs and services available to our members ... the growth and identity of our organization," said Emmanuel ...
Cached Medicine Technology:HUYA Biosciences Establishes Strategic Partnership with Sun Yat-sen University's School of Pharmaceutical Sciences 2HUYA Biosciences Establishes Strategic Partnership with Sun Yat-sen University's School of Pharmaceutical Sciences 3Nigerian Association of Pharmacists and Pharmaceutical Scientists in America (NAPPSA) Announces Prime Vendor Agreement with H. D. Smith 2
(Date:4/17/2015)... Texas (PRWEB) April 17, 2015 From the ... years ago, the Texas non-profit organization has empowered young people ... its effort to bring fresh water and the Gospel ... with Liberty University. Between March 17 and 27, students, faculty ... provide 7,000 Liberians with fresh water and the Good News ...
(Date:4/17/2015)... Rapids, MI (PRWEB) April 17, 2015 Enthusiasts ... CRUSH Grand Rapids, Saturday, April 25, 2015. The event will ... Reserve Wine & Food (201 Monroe Ave NW, Grand Rapids, ... from around the West Michigan area. Patrons are encouraged to ... of elegance and fun. , This year’s event will feature ...
(Date:4/17/2015)... April 17, 2015 Testosterone treatment ... class of prescription medications increases the likelihood that ... or other life-threatening cardiovascular event continue to mount ... Court, Northern District of Illinois. According to an ... Panel on Multidistrict Litigation (JPML) on April 15th, ...
(Date:4/17/2015)... 2015 The American College of Traditional Chinese Medicine ... Day on April 29. The event will be held from 11 ... 555 DeHaro St. in San Francisco, CA. , The agenda for ... at the DeHaro campus (room F), 11:10 a.m. – Introduction ... – Light lunch with current students, faculty and staff, 1 p.m. ...
(Date:4/17/2015)... Carolina (PRWEB) April 17, 2015 With ... Dental Care has spent the last four years ... care, performing procedures ranging from general cleanings to dental ... a grand opening at their new office in North ... same services as their Concord office, including denture fittings, ...
Breaking Medicine News(10 mins):Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 3Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 4Health News:American College of Traditional Chinese Medicine Hosts Open House 2
... , WASHINGTON, Nov. 24 New peer-reviewed data finding ... infected with chronic hepatitis C virus have received anti-viral therapy ... needs to move urgently on bipartisan legislation to support new ... Hepatitis Roundtable (NVHR) said today. , The ...
... study by researchers from Virginia Commonwealth University Medical Center ... fatty acids (PUFA) is associated with the progression of ... The study also found significantly higher plasma monounsaturated ... and NASH. Full findings appear in the December ...
... be on the hook for the high cost of drug advertising ... led by a University of British Columbia health policy researcher. ... Medicine , examined the US sales patterns of clopidogrel, a top-selling ... blood clots after heart attack or stroke. The drug was selected ...
... , American College of Medical Genetics ... National Family History Day, Thanksgiving 2009 , BETHESDA, Md., ... Family History Day, as declared by the U.S. Surgeon General. ... know their family medical history and if they haven,t already ...
... , HATBORO, Pa., Nov. 23 InfoLogix, Inc. ... enterprise mobility solutions for the healthcare and commercial industries, ... Managed Services at Siemens Health Services, has joined InfoLogix ... http://www.newscom.com/cgi-bin/prnh/20090618/NE35135LOGO ) , As Vice President of ...
... of arsenic compounds appears to cause oxidative DNA damage ... study published online November 23 in the Journal ... was once believed to detoxify inorganic arsenic, it is ... carcinogenicity. To assess the role of ...
Cached Medicine News:Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 2Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 3Health News:Metobolomics uncovers key indicators of nonalcoholic fatty liver disease 2Health News:Drug ads ineffective for boosting sales, could cost taxpayers: UBC-Harvard study 2Health News:'Family Health History and Genetics Privacy' is the Newest Addition to the ACMG Genetics & Your Health Video Series 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3
Lacrimal Cannula, Curved - Open End, 21gSize: 21g x 1-1/2"....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: